Know Cancer

forgot password

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

18 Years
Open (Enrolling)
Liver Tumors, Hepatocellular Carcinoma, Hepatoma, Neoplasms

Thank you

Trial Information

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

The purpose of this protocol is to provide supervised access at this institution to
TheraSphere® treatment for a heterogeneous population of patients with unresectable primary
liver tumors, with the liver being the only dominant site of disease. Based on experience
gained in previous studies and well-established interventional radiology techniques, this
protocol allows multiple treatments with TheraSphere® that may be delivered on an inpatient
or out patient basis. Patients may receive a single dose to the whole liver, or lobar
treatment delivered as a sequence of treatments approximately 30 - 90 days apart. The
investigator, working with co-investigators in radiation oncology, interventional radiology
and nuclear medicine, will develop a specific treatment plan for each patient, based upon
the presenting condition of the patient, the vascular anatomy, and the desired goal of

Inclusion Criteria:

- Confirmed diagnosis of hepatocellular carcinoma. The histopathology confirmation
criterion may be waived in patients with a radiographically identifiable liver mass
with known laboratory or clinical risk factors for cancer or elevated tumor markers
such as AFP (clinical diagnosis)

- Surgical evaluation must conclude the patient is not a candidate for resection or

- ECOG Performance Status Score 0 - 2.

- Age 18 years or older.

- Able to comprehend and provide written informed consent in accordance with
institutional and federal guidelines.

Exclusion Criteria:

Any pre-treatment laboratory findings within 15 days of treatment demonstrating:

- Absolute granulocyte count less than or equal to 1,500/ul

- Uncorrected Platelet count less than or equal to 75,000/ul

- Serum creatinine greater than or equal to 3.0 mg/dl

- Serum bilirubin greater than or equal to 2.0 mg/dl

- Any of the following contraindications to angiography and selective visceral
catheterization, 1.)History of severe allergy or intolerance to any contrast media,
narcotics, sedatives, or atropine, 2.) Bleeding diathesis, not correctable by usual
forms of therapy, and/or 3.) Severe peripheral vascular disease that would preclude

- Portal hypertension with portal venous shunt away from the liver.

- Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of
radiation to the lungs on either: 1) first TheraSphere® administration; or 2)
cumulative delivery of radiation to the lungs > 30 Gy over multiple treatments.

- Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
application of established angiographic techniques to stop such flow.

- Significant extrahepatic disease representing an imminent life-threatening outcome.

- Severe liver dysfunction (Childs' Classification C) or pulmonary insufficiency
(requiring continuous oxygen therapy).

- Active uncontrolled infection

- Significant underlying medical or psychiatric illness.

- Pregnant women may not participate.

- Children may not participate due to lack of clinical experience.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Evaluate patient quality of life and toxicities associated with TheraSphere® treatment

Outcome Time Frame:

24 months

Safety Issue:


Principal Investigator

Lawrence Wagman, M.D., F.A.C.S.

Investigator Role:

Principal Investigator

Investigator Affiliation:

St. Joseph Hospital of Orange


United States: Institutional Review Board

Study ID:

08-029 TheraSphere®



Start Date:

February 2009

Completion Date:

February 2016

Related Keywords:

  • Liver Tumors
  • Hepatocellular Carcinoma
  • Hepatoma
  • Neoplasms
  • Liver tumors
  • Liver cancer
  • Adult primary hepatocellular carcinoma
  • HCC
  • Hepatoma
  • Neoplasms
  • Neoplasms
  • Carcinoma
  • Liver Neoplasms
  • Carcinoma, Hepatocellular



The Center for Cancer Prevention & Treatment at St. Joseph Hospital of OrangeOrange, California  92868